3 results
Approved WMOCompleted
To prove superiority of Fermathron plus in the treatment of patients with mild knee OA compared to placebo
Approved WMOCompleted
Primary:The primary objective of Study 218MS305 is to determine whether prolonged-release fampridine (10 mg BID) has a clinically meaningful effect on patient-reported walking ability over a 24-week study period.Secondary:The secondary objectives…
Approved WMORecruiting
Primary:Part 1: PK, PD and SafetyTo assess the safety, tolerability and pharmacokinetics of multiple IV and SC doses of CFZ533 in combination with MMF, CS, and Tac (standard exposure) in de novo renal transplant patients over the treatment and…